Osteoporosis in men;Osteoporose des mannes

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 17, 2003, Pages 925-928

  Ringe, J D ^a  

^a KLINIKUM LEVERKUSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GESTAGEN; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ANDROGEN THERAPY; ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; HUMAN; MALE; OSTEOPOROSIS; PHYSIOTHERAPY; POSTMENOPAUSE; RISK FACTOR;

ALENDRONATE; ANDROGENS; CALCIUM CHANNEL BLOCKERS; DIAGNOSIS, DIFFERENTIAL; ETIDRONIC ACID; FRACTURES, BONE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPOGONADISM; MALE; OSTEOPOROSIS; PRIMARY PREVENTION; RISK FACTORS;

EID: 0038077158     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38842     Document Type: Article

References (17)

1. Allolio B, Dambacher M, Dreher R, Felsenberg D, Franke J, Kruse H-P, Leidig-Bruckner G, Ringe JD, Semler J, Willvonseder R, Ziegler R. Die Osteoporose des Mannes. Med Klinik 2000; 95: 327-338
2. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston S, Reeve J, Reid DM, Russell RGG, Stevenson JC. Management of male osteoporosis: report of the UK consensus group. QJ Med 1998; 91: 71-92
3. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069-3076
4. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610
5. Orwoll ES, Scheele WH, Clancy AD, Diez-Perrez A, Myers SL, Mitlak BH. Teriparatide therapy reduces the incidence of moderate or severe fractures in men with osteoporosis. NOF Fifth International Symposium: Clinical Advances in Osteoporosis, March 6-9, 2002, Honolulu, Hawaii, p.3.
6. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69: 242-247
7. Ringe JD. Osteoporosis in men. Martin Dunitz, London, In: Treatment of metabolic bone disease. Management strategy and drug therapy (Eds.: D.Hosking, JD Ringe). 2000
8. Ringe JD. Alendronsäure: Erstes Bisphosphonat zur Osteoporose-Therapie bei Männern. Arzneimitteltherapie 2001; 19: 111-114
9. Ringe JD. Osteoporose Dialog. 100 Fragen - 100 Antworten. (2. Auflage), Georg Thieme Verlag, Stuttgart, New York, 2003
10. Ringe JD, Dorst AJ, Faber H. Osteoporosis in men -clinical assessment of 400 patients and 205 controls by risk factor analysis, densitometry, and x-ray findings. Osteologie 1997; 6: 81-86
11. Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setnikar I. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monoflurophosphate. Osteoporos Int 2000; 8: 47-52
12. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 2001; 86: 5252-5255
13. Ringe JD, Rovati LC. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcified Tissue Int 2001; 69: 252-255
14. Ringe JD, Orwoll E, Daifotis A, Lombardi A. Treatment of male osteoporosis: Recent advances with alendronate. Osteoporos Int 2002; 13: 195-199
15. Ringe JD, Dauhrer K, Dorst A, Faber H. Three year treatment results with alendronate vs. alfacalcidol in established primary osteoporosis in men. J Bone Miner Res 2002; 17: S368(Suppl 1
16. Ringe JD, Dorst A, Faber H, Ibach K, Preuss J. Risedronate treatment of established primary and secondary osteoporosis in men: 1-year results of a 3-year prospective study. J Bone Miner Res 2002; 17: S368(Suppl 1)
17. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002; 17: 521-527